日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study

从非布司他换用新型选择性尿酸重吸收抑制剂多替努拉，可通过抑制 URAT1 显著降低血清尿酸水平，且可能不会对 ABCG2 功能产生不利影响：SWITCH SURI 研究结果

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2025.1655502
Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto
ITCH
ABCG2
发表日期：2025
文献求助 收藏

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial

伊美格列明可能通过延长2型糖尿病患者红细胞寿命来影响糖化血红蛋白A1c的准确性：来自INFINITY临床试验的启示

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2025.1699591
Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Shiozawa, Nana; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto
糖尿病
细胞生物学
红细胞
代谢
发表日期：2025
文献求助 收藏

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial

伊美格列明治疗2型糖尿病患者临床血糖控制指标及其对红细胞影响的比较评价：一项单臂、开放标签、前瞻性探索性试验的研究方案

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2023.1205021
Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto
代谢
糖尿病
红细胞
细胞生物学
发表日期：2023
文献求助 收藏

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia

达格列净可改善伴有肾性贫血的2型糖尿病患者的红细胞生成和铁代谢

期刊:Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
影响因子:3
doi:10.2147/DMSO.S411504
Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto
铁代谢
代谢
红细胞
糖尿病
细胞生物学
贫血
发表日期：2023
文献求助 收藏

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study

在伴有2型糖尿病肾病的高尿酸血症患者中，从非布司他换用新型选择性尿酸重吸收抑制剂多替努拉的疗效和安全性：一项单臂、开放标签、前瞻性探索性研究方案

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2022.1042061
Osonoi, Takeshi; Saito, Miyoko; Hosoya, Mitsuru; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto
糖尿病
糖尿病肾病
代谢
发表日期：2022
文献求助 收藏

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy

接受饮食疗法的2型糖尿病患者外周血白细胞中S100基因高表达

期刊:Drugs in Research & Development
影响因子:2.1
doi:10.1007/s40268-020-00334-z
Kondo, Shinnosuke; Mochizuki, Kazuki; Hariya, Natsuyo; Saito, Miyoko; Doguchi, Satako; Osonoi, Takeshi
糖尿病
细胞生物学
代谢
发表日期：2021
文献求助 收藏

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

DPP-4抑制剂联合治疗可能改善α-葡萄糖苷酶抑制剂和二甲双胍使用者的肾功能下降：一项回顾性观察研究

期刊:Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
影响因子:3
doi:10.2147/DMSO.S273405
Osonoi, Takeshi; Saito, Miyoko; Koda, Naoya; Douguchi, Satako; Nakano, Takako; Ofuchi, Kensuke; Katoh, Makoto
发表日期：2020
文献求助 收藏

Four-year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes

日本早期2型糖尿病患者自首次就诊以来四年的连续神经传导变化

期刊:Journal of Diabetes Investigation
影响因子:3
doi:10.1111/jdi.12583
Kobori, Mariko; Yagihashi, Soroku; Shiina, Norie; Shiozawa, Nana; Haginoya, Akiko; Ojima, Misato; Douguchi, Satako; Tamasawa, Atsuko; Saitou, Miyoko; Baba, Masayuki; Osonoi, Takeshi
糖尿病
代谢
发表日期：2017
文献求助 收藏